

All about Pre-filled Syringe Systems

From Initial Development to Final Fill Finish

Technical Aspects

Christa Jansen-Otten

Bernd Zeiss

Gothenburg, October 19th and 20th 2023



Agenda – DAY 1

Overview and Introduction into Pre-filled Syringe Market

Overview & Trends • Stakeholders • User's perspective

Technical Aspects

*Syringe • Plunger • Needle • Needle shield or Tip cap • Autoinjector •
Regulatory guidelines and technical standards*

Overview & Introduction into Drug-Syringe Interactions

Aggregation • Degeneration • Oxidation • Viscosity • Bubbles

Overview & Introduction to manufacturing Process of PFS

*Syringes Barrel Forming • Washing • Siliconization • Sterilization • Regulatory
guidelines and technical standards ...*

Fill and Finish

Filling • Stoppering • Assembly • Technical Standards

Hands-on Session 1

Requirements towards Injections and Ophthalmics*

- Packaging Description is part of the Registration Dossier
- Material in direct contact to the dosage form
- Storage/stability - transport - functionality (prefilled syringe is a device)
- Standards help all stakeholders

Protection

- ✓ Temperature
- ✓ Light
- ✓ Water loss
- ✓ Loss of solvent
- ✓ Oxygen
- ✓ Microbial ingress

Compatibility

- ✓ Adsorption
- ✓ pH change
- ✓ Precipitation
- ✓ Colour change
- ✓ Packaging brittleness

Safety

- ✓ Leachables
- ✓ Extractables
- ✓ Toxicity
- ✓ Glue or ink migration
- ✓ Breakage, drop test

Performance

- ✓ CCI
- ✓ Drug delivery
- ✓ NS pull off
- ✓ Break loose and gliding
- ✓ Usability: elderly people, children
- ✓ Connections

Prefilled Syringes to fulfill many needs

PFS makes the final drug product together with the formulation

- Chemical and pharmaceutical interface

Formulation - compatibility

- ✓ Stability
- ✓ Volume
- ✓ Concentration
- ✓ Interaction

Needs to work seamlessly in F&F

- Technical interface

Fill and Finish- manufacturing

- ✓ Accuracy
- ✓ Viscosity
- ✓ Machinability
- ✓ Stoppering method
- ✓ Plunger rod
- ✓ Label and blister

Syringe is packaging and device at the same time

- Physical interface to user

Patient/HCP - usability

- ✓ Functionality
- ✓ Sterility
- ✓ Leakage
- ✓ Accuracy of Dosing
- ✓ Safety of use
- ✓ Integration into AI


Regulatory Guidelines

Mainly Dimensions and Test methods


Relevant standards and regulations

- ISO 11040-4: Glass syringes ready for filling
- ISO 80369-7: Luer connectors
- ISO 11040-5: Plunger stoppers
- ISO 11040-6: Plastic syringes ready for filling
- ISO 11040-7: Nest & tub
- ISO 11040-8: Test methods for finished prefilled syringes
- ISO 9001: Quality management
- ISO 15378: GMP Primary packaging
- 21 CFR 211 Subpart E – Control of Components and Drug Product Containers and Closures
- DMF Type III
- Ph. Eur. USP and JP
- ASTM D4169-22 Shipping
- ASTM D6653-13 Plunger movement
- ...


0.5 ml	47.6	6.85	4.65
1.0 ml long	54.0	8.15	6.35
1.0 ml standard	35.7	10.85	8.65
1.5 ml	43.2	10.85	8.65
2.25 ml	54.4	10.85	8.65
3.0 ml	72.2	10.85	8.65
5.0 ml	66.8	14.45	11.85




PFS components - Pharmaco-chemical interfaces to the drug



PFS components: Physical interfaces to the drug



Does the syringe perform well with the formulation?




ISO 11040-8 is a good starting point

How suppliers can support ISO 11040-8

1. User requirements	Pharma or supplier data	2. Performance requirements	Pharma or supplier data
Definition of intended use	Pharma	Break loose and extrusion forces	Pharma, general performance data (water filled syr) from supplier
Risk management	Pharma, input from supplier	Burst resistance	supplier
Application of usability engineering	Pharma	Break resistance: LL, FF	supplier
System characterization	Pharma	Closure system forces and torques	supplier
Description of components and materials Barrel – Flange, barrel, cone, needle, cap	Critical dimesions, Geometry, Strength, Extractables (tungsten, glue, siliconization), Glass source, Cosmetic defects, sterilization, pull-off force cap, CCI cap	Connectivity with fluid path connectors	supplier
Description of components and materials Plunger stoppers	Critical dimensions, Elastomer material Compatibility, Extractables, Coating, Geometry, Siliconization, Sterilization	Residual volume	Pharma, general performance data (water filled syr) from supplier
Additional components: rod, backstop, Autoinjector, safety system...	Pharma: Device interactions of syringe barrel, Luer lock adapter with attached needle, autoinjector, needle safety device	Needle penetration force	Specification of supplier – not with tissue
Description of the content of the finished prefilled syringe	Pharma	Needle pull-out force	Specification of supplier
		Sharps injury protection requirements	Pharma
		Liquid leakage beyond plunger	Pharma, general performance data (water filled syr) from supplier
		Markings	Specification of supplier, accuracy t.b.tested by Pharma
		3. Pharmaceutical requirements	
		Drug-container interaction	Pharma, leachables, shear forces to be tested with drug
		Biological requirements	Pharma, general performance data (water filled syr) from supplier
		Container closure integrity (plunger)	Pharma, general performance data (water filled syr) from supplier
		Deliverable volume	Pharma, general performance data (water filled syr) from supplier
		Particles (visible and subvisible)	Pharma, general performance data (water filled syr) from supplier

Available from suppliers – can be supplied/tested without drug
 Pharma company input – no or limited data from supplier, drug needed

Syringe system with Autoinjector



Limit of syringes in Autoinjectors

- Dose volume < 3 ml
- Viscosity < 10 cP
- Subcutaneous application
- Mechanical (spring), ~10 s

→Wearables

- Dose volume > 3ml
- Viscosity > 10 cP
- Subcutaneous
- Electric drive, minutes


→Infusion

- Intravenous (vial + disposable syringe)
- home use limited


Regulatory Guidelines

ISO 10993-1 to-18
Biocompatibility:
Biological evaluation
of medical devices

- 1: Evaluation and testing
- 2: Animal welfare requirements
- 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- 4: Selection of tests for interactions with blood
- 5: Tests for in vitro cytotoxicity
- 6: Tests for local effects after implantation
- 7: Ethylene oxide sterilization residuals
- 8: Selection and qualification of reference materials for biological tests
- 9: Framework for identification and quantification of potential degradation products
- 10: Tests for irritation and delayed-type hypersensitivity
- 11: Tests for systemic toxicity
- 12: Sample preparation and reference materials
- 13: Identification and quantification of degradation products from polymeric medical devices
- 14: Identification and quantification of degradation products from ceramics
- 15: Identification and quantification of degradation products from metals and alloys
- 16: Toxicokinetic study design for degradation products and leachables
- 17: Establishment of allowable limits for leachable substances
- 18: Chemical characterization of materials



Global Pharmacopoeia




USP
U.S.
Pharmacopoeia

European
Pharmacopoei
a
10th Edition

PHARMACOPOEIA
OF THE PEOPLE'S
REPUBLIC OF CHINA

JP
Japanese
Pharmacopoeia

Overview of Relevant USP Chapters




Chapters > 1000 informational
 Chapters < 1000 mandatory if required by monograph

- <231> has been deleted
- ** will be official 2025


Overview of Relevant Ph Eur Chapters

European
Pharmacopeia
10th Edition




* 2.4.8 has been deleted

Overview of relevant JP Chapters



Examples of relevant YBB Standards


YBB



YBB standards are subsequently integrated into ChP for packaging material;
 16 already became obsolete when ChP2020 became effective Dec 2020


Extract of relevant ISO Standards

ISO




Extract of relevant ISO Standards

ISO



Regulations Are Evolving

Legacy Formula Timeline



EU GMP Annex I: at a glance

Background



- Revision of Annex I *Manufacture of Sterile Medicinal Products* of the EU Guidelines for good manufacturing practices for medicinal products
- Will be endorsed globally
- Focus on Contamination Control Strategy
- Introduced & strongly recommended RABS & Isolators
- Focus on assurance of Container Closure Integrity
- Knowledge and Experience of the Container Closure System
- Primary Packaging components are also in scope

What does this mean for you



- Need to prove compliance
- Need to have a contamination control strategy document
- Information from suppliers is part of this



Medical Device Regulation: At A Glance

Background




- Revision of Regulation 2017/745 on medical devices (MDR)
- Prefilled Syringe is a medical device
- MAA needs a Notified Body Opinion (NBOp)
- Need to fulfill Annex I General Safety and Performance Requirements (GSPRs)
- GSPRs have been expanded significantly
- Knowledge and Experience of the Container Closure System
- Primary Packaging components are also in scope

What does this mean for you



- Need to obtain a NBOp
- Information from suppliers is part of this



Summary – Technical aspects

- Many physical and chemical factors to consider
- PFS is both drug delivery device and primary packaging container
- Component suppliers become system suppliers
- Regulation for prefilled syringes is complex – start with ISO standards
- Comprehensive documentation and testing necessary
- Risk management:
 - Start with ISO standards - finish with risk assessment
 - Regulations are evolving, two main topics Annex 1 and MDR
- Closer cooperation with component manufacturers necessary in future

Sources

- FDA Guidance Container Closure Systems for Packaging Human Drugs and Biologics
- ISO 11040-4: Glass syringes ready for filling
- ISO 80369-7: Luer connectors
- ISO 11040-5: Plunger stoppers
- ISO 11040-6: Plastic syringes ready for filling
- ISO 11040-7: Nest & tub
- ISO 11040-8: Test methods for finished prefilled syringes
- ISO 9001: Quality management
- ISO 15378: GMP Primary packaging
- ISO 10993-1 to -18
- 21 CFR 211 Subpart E – Control of Components and Drug Product Containers and Closures
- Ph. Eur. USP and JP
- ASTM D4169-22 Shipping
- ASTM D6653-13 Plunger movement
- Development of Biopharmaceutical Drug-Device Products. PFS characterization and Interaction with Biologic Formulations. David A. Post, Sherwin Shang, Shweta A. Raina, William Szechinski. AAPS Advances in the Pharmaceutical Sciences Series 35, 2019 - 831 ff
- Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements: Advait V Badkar, Rajesh B Gandhi, Shawn P Davis & Michael J LaBarre (2021), Drug Design, Development and Therapy, 15:, 159-170, DOI: 10.2147/DDDT.S287323
- Structure of Technical Documentation (Medical Devices) (mdc-ce.de)